您也會有興趣的產品：
Tenofovir Disoproxil Fumarate
Tenofovir was approved by the FDA in 2001 for use in combination with other antiretroviral agents in adults with HIV infection. This recommendation was based primarily on a randomized, placebo-controlled study of HIV treatment-experienced individuals with detectable viral load on stable combination antiretroviral therapy. The addition of tenofovir to the existing regimen resulted in a significant decrease in viral load at week 24 of the study (0.61 log10 average decrease in viral load from baseline, compared with 0.03 log10 decrease in the placebo group; p < .0001). An increase in CD4 count of 12.6 cells/µL was seen in the tenofovir group, compared with a decrease of 10.6 cells/µL in the placebo group (p = .0008).(1) In 2012, FDA approval was extended to pediatric patients 2 years of age and older. VIREAD is the brand name for tenofovir disoproxil fumarate (a prodrug of tenofovir) which is a fumaric acid salt of bis-isopropoxycarbonyloxymethyl ester derivative of tenofovir. In vivo ten
主要產品:
chemical
